NCT06428500View on ClinicalTrials.gov

QTX3046 in Patients With KRAS G12D Mutations

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

QTX3046

QTX3046 will be administered at protocol defined dose.

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Trial Locations (5)

27705

Duke Cancer Center, Durham

49546

South Texas Accelerated Research Therapeutics, LLC Midwest, Grand Rapids

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, LLC San Antonio, San Antonio

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

Quanta Therapeutics

INDUSTRY

NCT06428500 - QTX3046 in Patients With KRAS G12D Mutations | Biotech Hunter | Biotech Hunter